Legend Biotech Corp (NASDAQ: LEGN) — Company Overview, News & Financial Data
Legend Biotech develops CAR-T cell therapies for oncology, focusing on advancing treatments for multiple myeloma.
Legend Biotech Corp
Legend Biotech (NASDAQ:LEGN) is a global biotech firm focused on discovering, developing, and commercializing cell therapies for oncology and other life-threatening diseases. Their robust pipeline includes candidate treatments that leverage innovative technologies, particularly in the realm of CAR-T cell therapies aimed at improving patient outcomes in areas of high unmet need. One of their notable projects is the advancement of therapies targeting multiple myeloma, showcasing their commitment to pushing the boundaries of medicine. With a mission to transform the lives of patients by harnessing the power of cutting-edge science, Legend Biotech is dedicated to achieving breakthroughs that could redefine treatment paradigms. The company's work spans multiple continents, reflecting its global approach to tackling critical healthcare challenges.
Snapshot
Operations
Products and/or services of Legend Biotech Corp
- CAR-T cell therapies for multiple myeloma, focusing on cilta-cel, a leading treatment providing significant remission rates in relapsed/refractory patients.
- Cell therapy technologies, including genetically engineered T cells targeting cancer-specific antigens for personalized patient care.
- Collaborative research and development agreements with pharmaceutical companies to advance cell therapy in oncology and beyond.
- Research in solid tumors aiming to expand the applicability of CAR-T and other cell therapies to a broader range of cancers.
- Manufacturing capabilities for cell therapies, ensuring quality control and scalability from clinical trials to commercialization.
- Pipeline development in hematology, expanding beyond multiple myeloma to address unmet needs in other blood cancers through innovative cell therapy approaches.
Legend Biotech Corp executive team
- Ingrid ZhangChief Executive Officer
- Carlos Santos GarciaChief Financial Officer
- Ananda Elizabeth MartinGlobal Compliance Officer
- Robert StaloffGeneral Counsel
- Yuhong QiuInterim Head of Research & Development and Senior VP of Regulatory Affairs
- Birk VanderweeenSenior Vice President of Global Manufacturing & Supply
- Alan S. BashPresident of CARVYKTI Business Unit
- Surabhi VermaManager of Investor Relations & Corporate Communications
- Joanne ChoiSenior Manager of Investor Relations
Latest news about Legend Biotech Corp
Legend Biotech reports five-year CARVYKTI data
United StatesLegend Biotech appoints Alan Bash as interim CEO
United StatesLegend Biotech dual-target CAR-T shows early efficacy in lymphoma
United StatesLegend Biotech highlights solid tumor advance and long-term multiple myeloma survival at ASCO 2026
United StatesLegend Biotech nears profitability as CARVYKTI sales jump 62% in Q1
United StatesLegend Biotech achieves CARVYKTI franchise profitability on $1.9B in 2025 sales
United States
Key financials
Reported results for Legend Biotech Corp, in USD.
- Market cap
- 4.2B
- Revenue (TTM)
- 1.3B
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.5
- Dividend yield
- —
- Profit margin
- -7.2%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1B | -136.5M | -296.8M | |
| 627.2M | -303.2M | -177M | |
| 285.1M | -439.5M | -518.3M | |
| 117M | -455.6M | -446.3M |